Efficiency of bevacizumab in treatment for relapsing ovarian cancer: case report
Authors:
Zuzana Donátová; Jitka Abrahámová
Authors‘ workplace:
Onkologická klinika, 1. LF UK a Thomayerova nemocnice, Praha, primářka prof. MUDr. Jitka Abrahámová, DrSc.
Published in:
Prakt Gyn 2013; 17(3): 209-215
Category:
Oncogynecology: Case report
Overview
Ovarian cancer (epithelial ovarian cancer – EOC) is a gynecological malignancy with the worst prognosis. It is considered a chemosensitive disease. Paclitaxel and carboplatin chemotherapy was (till 2011) more than 15 years the standard treatment regime. New hope for patients with ovarian cancer is chemotherapy combined with targeted antiangiogenic therapy with bevacizumab. Bevacizumab is a humanized monoclonal antibody against key factor in angiogenesis, vascular endothelial growth factor (VEGF). There is its efficiency is proven and demonstrated in a number of cancers. Described case of patient shows the contribution of addition of bevacizumab to chemotherapy in repeatedly relapsed ovarian cancer according to the results of clinical research.
Key words:
bevacizumab – chemotherapy – epithelial ovarian cancer – antiangiogenic therapy
Sources
1. ÚZIS ČR. NOR ČR. Novotvary 2009. ÚZIS ČR, NOR ČR 2012. ISBN 978–80–7280–975–2 Dostupné i z WWW: <http:// www.uzis.cz/publikace/novotvary-2009>.
2. Ramakrishnan S, Subramanian IV, Yokoyama Y et al. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005; 8(2): 169–182.
3. Burger RA, Brady MF, Bookman MA et al. Gynecologic Oncology Group. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med 2011; 365(26): 2473–2483.
4. Perren TJ, Swart AM, Pfisterer J et al (ICON 7 Investigators). A phase 3 trial of bevacizumab in ovarian Cancer. N Engl J Med 2011;365(26): 2484–2496.
5. Aghajanian C, Finkler NJ, Rutherford T et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). ASCO Annual Meeting Proceedings (Post-Meeting Edition; Annual Meeting Chicago June 4–8). J Clin Oncol 2011; 29(18, Suppl): Abstract LBA5007.
6. Aghajanian C, Blank SV, Goff BA et al. An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer. J Clin Oncol 2012; 30(15, Suppl), ASCO Annual Meeting Proceedings (Post-Meeting Edition; Annual Meeting Chicago): Abstract 5054.
7. Aghajanian C, et al. OCEANS: Updated overall survival analysis in OCEANS, a randomised phase 3 trial of gemcitabine (G) + carboplatin ( C ) and bevacisumab (BV) or placebo (PL) follow by BV or PL in platium sensitive recurrent epithelial ovaria (ROC) , primary peritoneal (PPC), or Fallopian tube cancer (FTC). 2012 Program and abstracts of the 2012 Annual Congress of the European Society for Medical Oncology, Abstract 9670.
8. Pujade- Lauraine E, Hilpert F et al (AURELIA Investigators). A randomised phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)- resistant recurrent ovarian cancer (OC) J. Clin Oncol 2012; 30(18, Suppl 2012 ASCO Annual Meeting Abstracts LBA 5002.
9. Poveda AM, Selle F, Hilpert F et al. Weekly paclitaxel ( PAC) pegylated liposomal doxorubicin ( PLD) or topotecan ( TOP) +/- bevacizumab ( BEV) in platinum ( PT)- resistant recurrent ovarian cancer (OC) : analysis by chemotherap y ( CT( cohort in the GCIG AURELIA randomised phase III trial. Program and abstracts of the 2012 Annual Congress of the European Socienty for Medical Oncology, Abstract LBA 26
10. Modrá kniha České onkologické společnosti JEP, 16. vyd. Masarykův onkologický ústav 2013: kap. 9.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2013 Issue 3
Most read in this issue
- Hysteroscopic sterilization by system Essure in gynecologic practice: new technology of permanent contraception
- Antiadhesive agents in laparoscopic surgery
- When to refer a patient to venerologist?
- Determinants of health literacy of pregnant women